|
|
|
Who Classification of Tumours of the Central Nervous System (Who Classfication of Tumours)
WHO Classification of Tumours of the Central Nervous System is the first volume of the 4th Edition of the World Health Organization series on histological and genetic typing of human tumours. This authoritative, concise reference book provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome. Diagnostic criteria, pathological features, and associated genetic alterations are described in a strictly disease-oriented manner. Sections on all recognized neoplasms and their variants include new ICD-O codes, incidence, age and sex distribution, location, clinical signs and symptoms, pathology, genetics, and predictive factors. The book, prepared by 73 authors from 19 countries, contains more than 400 colour photographs, numerous X-rays, computed tomography (CT), magnetic resonance (MR) images, charts, and more than 2,500 references..
Price: $93.20
[ Notify me when price goes down.]
|
|
Pathology And Genetics of Tumours of the Soft Tissues And Bones (World Health Organization Classification of Tumours)
|
|
WHO Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs (World Health Organization Classification of Tumours)
This new volume in the WHO series on histological and genetic typing of human tumours covers tumours of the kidney, the urinary system, the prostate, the testis and paratesticular tissue and the penis. Each entity is extensively discussed with information on clinicopathological, epidemiological, immunophenotypic and genetic aspects of these diseases. This book is an authoritative, concise reference, prepared by 131 authors from 22 countries. It contains more than 800 colour photographs, numerous MRIs, ultrasound images, CT scans, charts and 3000 references..
Price: $71.25
[ Notify me when price goes down.]
|
|
World Health Organization: Tumours of the Breast and Female Genital Organs (Who/IARC Classification of Tumours) (Who/IARC Classification of Tumours)
This WHO classification covers the female and male breast, ovaries, fallopian tumours, uterine cervix, uterine corpus, vulva, vagina and inherited tumour syndromes It includes a comprehensive classification of benign and malignant neoplasms. Targeted readership includes pathologists, gynaecologists, surgeons, oncologists, and basic scientists. Similar to the previous volumes of the series, the book includes numerous colour photographs, magnetic resonance images, CT scans and charts. In addition to its pathology and genetics, each lesion is described with its epidemiology, etiology, clinical features, as well as prognosis and predictive factors..
Price: $73.90
[ Notify me when price goes down.]
|
|
Pathology & Genetics of Tumours of the Lung, Thymus And Heart (World Health Organization Classification of Tumours)
This book is an authoritative, concise reference, prepared by 200 authors from 25 countries It contains more than 670 colour photographs, numerous MRIs, ultrasound images, CT scans, charts and approximately 2,200 references. Diagnostic criteria, pathological features and associated genetic alterations are described in a strictly disease-oriented manner. Sections on all recognized neoplasms and their variants include new ICD-O codes, incidence, age and sex distribution, location, clinical signs and symptoms, pathology, genetics and predictive factors..
Price: $306.34
[ Notify me when price goes down.]
|
|
Cancer Stem Cells: Novel Concepts and Prospects for Tumor Therapy (Ernst Schering Foundation Symposium Proceedings)
Cancer stem cells werehave originally been identified in leukemia and later in several solid tumor types. They have very different properties from the bulk of the tumor, as they divide much more slowly and have very efficient drug- resistance mechanisms. Current treatments might largely spare cancer stem cells, thus leading to tumor recurrence and metastasis. The recent identification of growth and differentiation pathways responsible for cancer stem cell proliferation and survival will help in the discovery identification of novel therapeutic targets. Developing selective drugs against cancer stem cells offers great therapeutic opportunities but also provides for major challenges regarding preclinical models, therapeutic windows, and clinical study end points. .
Price: $79.98
[ Notify me when price goes down.]
|
|
|
|
|